It’s been a crucial week for La Jolla Pharmaceutical Company (NASDAQ:LJPC); here’s what analysts have to say.

February 15, 2018 - By Rusty Cady

 It's been a crucial week for La Jolla Pharmaceutical Company (NASDAQ:LJPC); here's what analysts have to say.
Investors sentiment decreased to 1.61 in Q3 2017. Its down 0.20, from 1.81 in 2017Q2. It fall, as 10 investors sold La Jolla Pharmaceutical Company shares while 21 reduced holdings. 25 funds opened positions while 25 raised stakes. 23.31 million shares or 1.99% less from 23.78 million shares in 2017Q2 were reported.
Moreover, Rhumbline Advisers has 0% invested in La Jolla Pharmaceutical Company (NASDAQ:LJPC) for 20,247 shares. Ubs Asset Mgmt Americas has invested 0% in La Jolla Pharmaceutical Company (NASDAQ:LJPC). Blackrock owns 1.16M shares or 0% of their US portfolio. Barclays Public Llc stated it has 0% of its portfolio in La Jolla Pharmaceutical Company (NASDAQ:LJPC). Nationwide Fund Advisors has 0% invested in La Jolla Pharmaceutical Company (NASDAQ:LJPC). State Bank Of Montreal Can owns 10,899 shares. Bankshares Of Mellon has 83,744 shares. Bluecrest Cap Mgmt has 18,454 shares. Metropolitan Life Insur Commerce New York invested 0% of its portfolio in La Jolla Pharmaceutical Company (NASDAQ:LJPC). Alliancebernstein Limited Partnership stated it has 0% of its portfolio in La Jolla Pharmaceutical Company (NASDAQ:LJPC). Swiss Bancorporation accumulated 0% or 29,400 shares. Legal And General Public Llc has 4,429 shares for 0% of their portfolio. Eam Lc holds 47,557 shares. Zurcher Kantonalbank (Zurich Cantonalbank) invested in 1,523 shares or 0% of the stock. Hollencrest Secs Ltd holds 0.11% of its portfolio in La Jolla Pharmaceutical Company (NASDAQ:LJPC) for 22,092 shares.

Since December 29, 2017, it had 0 insider buys, and 1 sale for $323,208 activity.

La Jolla Pharmaceutical Company (NASDAQ:LJPC) Ratings Coverage

Among 8 analysts covering La Jolla Pharmaceutical Company (NASDAQ:LJPC), 5 have Buy rating, 3 Sell and 0 Hold. Therefore 63% are positive. La Jolla Pharmaceutical Company had 18 analyst reports since August 11, 2015 according to SRatingsIntel. The stock has “Buy” rating by Jefferies on Monday, June 12. The stock of La Jolla Pharmaceutical Company (NASDAQ:LJPC) earned “Buy” rating by J.P. Morgan on Wednesday, August 30. The rating was maintained by Jefferies with “Buy” on Thursday, August 31. The rating was downgraded by Jefferies on Monday, February 12 to “Underperform”. The firm has “Hold” rating by Zacks given on Tuesday, August 11. JP Morgan downgraded the stock to “Underweight” rating in Friday, December 8 report. The firm has “Buy” rating by Cowen & Co given on Friday, December 22. The stock has “Buy” rating by H.C. Wainwright on Tuesday, January 30. The company was maintained on Monday, July 24 by Jefferies. The firm has “Buy” rating by Lake Street given on Tuesday, May 24. Below is a list of La Jolla Pharmaceutical Company (NASDAQ:LJPC) latest ratings and price target changes.

12/02/2018 Broker: Jefferies Old Rating: Buy New Rating: Underperform Downgrade
30/01/2018 Broker: H.C. Wainwright Rating: Buy Maintain
22/12/2017 Broker: Cowen & Co Rating: Buy New Target: $55.0 Maintain
22/12/2017 Broker: Chardan Capital Markets Rating: Buy New Target: $90.0
22/12/2017 Broker: SunTrust Rating: Buy
21/12/2017 Broker: H.C. Wainwright Rating: Buy New Target: $62 Initiates Coverage On
08/12/2017 Broker: J.P. Morgan Rating: Sell New Target: $20.0 Downgrade
08/12/2017 Broker: JP Morgan Old Rating: Overweight New Rating: Underweight Old Target: $36 Downgrade
27/10/2017 Broker: Cowen & Co Rating: Buy New Target: $55.0
31/08/2017 Broker: Jefferies Rating: Buy New Target: $40.0 Maintain

The stock decreased 1.64% or $0.535 during the last trading session, reaching $32.195. About 211,595 shares traded. La Jolla Pharmaceutical Company (NASDAQ:LJPC) has risen 128.65% since February 15, 2017 and is uptrending. It has outperformed by 111.95% the S&P500.

La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. The company has market cap of $712.97 million. It engages in developing LJPC-501, a formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension; and LJPC-401, a formulation of synthetic human hepcidin for the treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease, and myelodysplastic syndrome. It currently has negative earnings. The firm is also developing LJPC-30S, which is the gentamicin derivative program for the potential treatment of serious bacterial infections and rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy.

Another recent and important La Jolla Pharmaceutical Company (NASDAQ:LJPC) news was published by Fool.com which published an article titled: “Why Lumber Liquidators Holdings, Stamps.com, and La Jolla Pharmaceutical …” on February 12, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.